- LOGIN
- MemberShip
- 2025-12-17 18:43:59
- Company
- "Lirafugratinib demonstrated to selectively inhibit FGFR2"
- by Hwang, byoung woo Oct 24, 2025 06:13am
- Clinical data for HLB’s FGFR2-targeted anti-cancer drug, 'lirafugratinib,' were presented at the ESMO Congress 2025 (European Society for Medical Oncology). Professor Richard Kim of the Moffitt Cancer Center in the U.S., who participated as a clinician in the study, discussed lirafugratinib’s differentiation, clinical significance, and potential for future approval with DailyPharm at the conference. Professor Kim explained, "Biliary tract cancer (BTC) remains a rare cancer with limited treatment options. The small patient population and high development difficulty have slowed the introduction of new drugs," and added, "In the U.S., about 12,000-14,000 new cases are diagnosed annually, and FGFR2 fusions are confirmed in 10-15% of these patients." He further stated, "The first-line standard of care is chemotherapy combined with immunotherapy. For second-line and later lines, FOLFOX is primarily used, but response rates are low. Identifying the FGFR2 mutation is a key step that opens new treatment opportunities." Selective FGFR2 inhibition…reduces toxicity, overcomes resistance Professor Richard Kim of the Moffitt Cancer Center in the U.S.In the poster presentation at ESMO Congress 2025, Professor Kim shared data on the response rate and tolerability of lirafugratinib in patients with BTC and non-BTC solid tumors harboring FGFR2 alterations. This presentation expanded on the interim results previously disclosed at ENA 2024 ('ReFocus' study), strengthening the follow-up clinical evidence focused on the FGFR2 mutation. Professor Kim said, "Existing approved drugs, such as pemigatinib (Pemazyre) and futibatinib (Lytgobi), are Pan-FGFR agents that inhibit FGFR1-4, often leading to FGFR1-related toxicity." He emphasized, "Lirafugratinib significantly enhances safety by selectively inhibiting only FGFR2." According to HLB, lirafugratinib is designed as an irreversible FGFR2-selective inhibitor. Through a motion-based drug design strategy based on molecular dynamics (MD) simulations, it minimizes binding to FGFR1, 3, and 4, thereby lowering toxicity while enhancing FGFR2 selectivity. In the clinical trial, treatment-related adverse events (TRAEs) reported were mostly low-grade, reversible, and manageable with dose adjustments, with a treatment discontinuation rate of less than 2%. Off-isoform toxicities, such as hyperphosphatemia and diarrhea, were rarely observed. Professor Kim assessed that "Lirafugratinib has more potent FGFR2 inhibition compared to existing drugs and showed activity even in areas where existing drugs have shown resistance, such as gatekeeper mutations and kinase domain mutations," and added, "Anti-cancer activity was observed not only in FGFR2 fusions but also in amplification and mutations." " Response observed in resistant patients…a 2nd-generation inhibitor" At ESMO Congress 2025, Professor Kim defined lirafugratinib as a 2nd-generation FGFR inhibitor that addresses the limitations of 1st-generation FGFR inhibitors. He noted, "If pemigatinib and futibatinib are 1st-generation, lirafugratinib is a 2nd-generation FGFR2 inhibitor capable of overcoming resistance and managing multiple mutations." He added, "Anti-cancer response was observed not only in patients without prior FGFR inhibitor experience but also in patients who developed resistance to existing drugs." According to the ReFocus clinical results presented at the ESMO Congress 2025 and the ENA 2024, the objective response rate (ORR) was 37% in patients with non-CCA (non-biliary tract cancer) solid tumors harboring FGFR2 fusions. The median duration of response (DoR) was 7.3 months, and the 6-month response maintenance rate was 61%. Notably, response rates of 75% were reported in NSCLC patients, 46% in pancreatic cancer, and 67% in ovarian cancer, showing meaningful therapeutic effects across various solid tumors with FGFR2 alterations. Expanded uner the tumor-agnostic strategy…"Targeting the FGFR2 mutation" Another core aspect of lirafugratinib development is its 'tumor-agnostic' strategy. The FGFR2 mutation is commonly found in over 10 types of solid tumors, including BTC, pancreatic, lung, breast, ovarian, and gastric cancers. Professor Kim stated, "Lirafugratinib targets the FGFR2 mutation itself, not a specific cancer type." He added, "This approach provides a basis for future expansion into various solid tumors as a combination or monotherapy." The ReFocus study also showed that the non-BTC patient population accounted for over half of the total patients, and a similar anti-cancer response pattern was observed across various solid tumors with FGFR2 mutations. This strategy differs from existing FGFR inhibitors, which primarily target a single cancer type. Currently, HLB reportedly plans to submit a New Drug Application (NDA) for lirafugratinib's BTC indication to the U.S. FDA as early as this year, or by early next year. Professor Richard Kim expressed an optimistic outlook regarding the likelihood of future approval. Professor Kim emphasized, "Based on the data so far, we believe approval is possible. Once the clinical results are finalized, it will be a sufficiently strong candidate for FDA approval." He also said, "Lirafugratinib is a well-balanced drug in terms of both efficacy and safety," and added, "As more clinical evidence accumulates, its introduction as a first-line treatment that could potentially replace chemotherapy is considerable." Meanwhile, HLB and its subsidiary, Elevar Therapeutics, are preparing to present the primary efficacy data for lirafugratinib at ASCO GI 2026.
- Company
- BTN1A1 effective in PD-L1–negative, resistant tumors
- by Hwang, byoung woo Oct 23, 2025 06:12am
- STCube is venturing into one of immuno-oncology’s uncharted territories. The company has been exploring therapeutic responses of its first-in-class BTN1A1-targeting drug candidate, Nelmastobart, in patients with PD-L1–negative or PD-1-resistant tumors, marking the first step toward realizing precision immunotherapy. At the European Society for Medical Oncology (ESMO) 2025 Congress, STCube presented two studies: an investigator-initiated trial and a preclinical study. The investigator-initiated trial demonstrated a correlation between BTN1A1 expression levels and progression-free survival, while the preclinical study showed the complementary effect of BTN1A1 inhibition when combined with chemotherapy. Dailypharm met with Seung-han Yoo, Chief Scientific Officer (CSO) of STCube, and Soo-hyeon Lee, Professor of Medical Oncology at Korea University Anam Hospital, in Berlin to discuss the significance of the research and future plans. Poster Presentation by Professor Soo-hyeon Lee (Korea University Anam Hospital) “Efficacy observed in PD-L1–negative patients, new potential found for precision immunotherapy” According to the company, BTN1A1 is a target first identified globally by STCube and is an immune checkpoint protein that acts independently of PD-L1. BTN1A1 shows minimal expression in normal tissues but high expression in tumor cells, making it both a therapeutic target and a potential predictive biomarker. CSO Yoo explained, “BTN1A1 is highly expressed in tumors where PD-L1 is rarely expressed, particularly colorectal cancer and non-small cell lung cancers. It has the potential to open a new response pathway in patient groups unresponsive to existing immune checkpoint inhibitors.” The ESMO presentation featured interim analysis results from an ongoing Phase 1b/2 investigator-initiated clinical trial for metastatic colorectal cancer at Korea University Anam Hospital, focusing on differences in progression-free survival by degree of BTN1A1 expression. The preclinical poster confirmed that BTN1A1 expression actually increases after chemotherapy. CSO Yoo stated, “Unlike how PD-L1 is primarily expressed in rapidly growing tumor cells, BTN1A1 is highly expressed in slow-growing cells that remain after treatment—specifically, dormant tumor cells. This allows for a complementary effect when combined with chemotherapy.” He added, “In the study, tumor suppression was significantly enhanced when BTN1A1 inhibitors were co-administered with standard anticancer drugs like FOLFOX (folinic acid + fluorouracil + oxaliplatin) and FOLFIRI (folinic acid + fluorouracil + irinotecan) for colorectal cancer, FOLFIRI for lung cancer, and docetaxel for lung cancer. The findings suggest we could consider adopting a combination strategy for patients resistant to PD-1 inhibitors.” “Extends revival in BTN1A1-High patients... will acclerate biomarker clinical trials” A correlation between BTN1A1 expression levels and clinical response was also observed in the ongoing colorectal cancer investigator-initiated clinical trial (Phase 1b/2) at Korea University Anam Hospital. STCube CSO Seung-han Yoo CSO Yoo, analyzed, “The higher the BTN1A1 expression, the more pronounced the response. The median progression-free survival (mPFS) was 6.3 months in the patient group with a BTN1A1 H-Score of 250 or higher, 4.2 months in the 150-249 group, and 4.0 months in the group below 150.” These results represent an improvement over the average 2-3 months seen with existing standard third-line therapies. Based on this, the company is actively advancing its biomarker-based clinical strategy targeting BTN1A1-positive patients and is preparing to initiate dosing in its company-led Phase II trial for non-small cell lung cancer by the end of this year. On this day, Professor Lee summarized the clinical significance of the BTN1A1 inhibitor into four points, in addition to the explanation provided by CSO Yoo. “It presents new possibilities for cancer types unresponsive to existing PD-1-centric therapies and can serve as a combination partner for PD-1-resistant or refractory patients. Alongside the significance of biomarker-based clinical design, its minimal toxicity when combined positions it to evolve into a safe immuno-oncology platform.” Professor Lee further evaluated, “While PD-1 combination therapy can sometimes cause unexpected immune-related adverse reactions, BTN1A1 inhibitors do not add toxicity when combined with existing drugs. In fact, their high safety profile makes them suitable as new combination partners.” Lee added that no immune-related adverse reactions were reported in actual patient administration, but noted that confirming long-term and large-scale safety remains a subsequent task. “Will build data and explore global collaboration… to realize precision immunotherapy” The company plans to use these results as clinical evidence for its BTN1A1-based precision immunotherapy platform and accelerate the expansion of its subsequent pipeline. Specifically, it intends to secure additional clinical data for colorectal and lung cancer by early next year and then formally initiate technology transfer discussions with global pharmaceutical companies. In the long term, the strategy is to build a precision immunotherapy portfolio centered on BTN1A1 inhibitors to address unmet needs in the post-PD-1 market. CSO Yoo added, “BTN1A1 could be the missing link explaining immune responses not accounted for by PD-L1. We will work step-by-step to demonstrate the potential of precision immuno-oncology through clinical data.”
- Company
- "AI pathology analysis changes trt paradigm…Lunit presents"
- by Hwang, byoung woo Oct 23, 2025 06:11am
- At the European Society for Medical Oncology conference (ESMO Congress 2025), Lunit presented new clinical evidence for its Artificial Intelligence (AI) pathology analysis. The results are particularly significant as Lunit demonstrated that AI can distinguish treatment response in a subset of proficient mismatch repair (pMMR) colorectal cancer (CRC) patients, a group that typically shows little response to immunotherapy. DailyPharm met with Im Yu-ju, Medical Director of Lunit's Oncology Group (Hematology-Oncology Specialist), at ESMO 2025 to discuss the clinical significance and future vision of the research. Oral presentation by Lunit at the ESMO Congress 2025. "Predicting treatment response from a single Slide... AI biomarker proves utility" Lunit presented two abstracts utilizing its AI biomarker platform, Lunit SCOPE. In particular, Oral Presentation detailing the results of a joint study with Professor Chiara Cremolini's research team at the University of Pisa garnered attention. The study's core objective was to predict the therapeutic effect of atezolizumab (Tecentriq) combination therapy using Lunit's AI pathology platform, 'Lunit SCOPE.' Im explained, "pMMR colorectal cancer is a notoriously intractable cancer that barely responds to immunotherapy. However, this study allowed us to identify a specific patient subgroup that benefits from the addition of immunotherapy." Im emphasized, "We quantified the tumor microenvironment (TME) using only conventional H&E (Hematoxylin & Eosin-stained slide) slides, without the need for new tests or tissue collection, to predict treatment response. This result shows that AI can possess clinical utility as a biomarker." H&E slides are standard stained tissue slides made from most patient specimens during pathological diagnosis. The clinical applicability is high because they can be used without additional testing. In the study, researchers analyzed pathology slides from 161 patients using Lunit SCOPE to quantify the density of six cell types, including lymphocytes and tumor cells. Subsequently, they stratified patients into two groups (A/B). The analysis showed that in the atezolizumab combination group, Group A demonstrated improvement in both progression-free survival (PFS) and overall survival (OS) compared to Group B. Notably, this difference was observed only in the combination arm, but not in the chemotherapy monotherapy group, proving Lunit SCOPE to be an immunotherapy-specific predictive indicator. "AI incorporated complex immune response...AI refines tumor microenvironment analysis" The key finding of this research is its complex interpretation of the tumor microenvironment (TME), moving beyond simple cell density analysis. Im stated, "The response to immunotherapy is a comprehensive result of complex immune factors, including T-cell infiltration, antigen presentation pathways, and neoantigens, not just PD-L1 expression." She added, "Lunit SCOPE quantifies these multi-layered variables through AI pathology analysis and presents them in an interpretable format." Im Yu-ju, Medical Director of LunitIn particular, this model moved beyond the traditional inflamed-centric classification by incorporating the interplay between various cells, including endothelial cells and fibroblasts. Im added, "Along with lymphocyte distribution, the proportion of dividing tumor cells was the highest contributor to predicting response," and said, "AI has overcome the limitations of conventional single-factor-based biomarkers." Furthermore, Im said, "Although it varies by slide size, the analysis of a single slide typically takes 5–10 minutes. Even large-volume data can be processed within tens of minutes." She stated, "This speed allows the results to be immediately referenced concurrently with the clinical interpretation process." Lunit, which has attended ESMO for five consecutive years since 2021, is leveraging this research to expand collaboration discussions with global pharmaceutical companies. Im said, "Since many immune checkpoint inhibitors are already approved, collaboration is more active in companion diagnostics for subsequent indications and new drug development, rather than new clinical trials," and added, "We are accumulating evidence through investigator-initiated clinical trial data," "We are concurrently researching biomarkers for next-generation anti-cancer drugs like BiTE (Bispecific T-cell Engager) and ADC based on Lunit SCOPE IO," said Im and mentioned, "Our goal is to establish the technology as a practical treatment predictive tool through collaboration with partner pharmaceutical companies from the clinical trial stage." "AI, a New Partner in Drug Development... Expanding to ADC and TKI" At the annual ESMO conference, presentations on new modalities, such as ADCs, are consistently featured alongside those on immunotherapies. Lunit is also expanding its AI biomarker research in these areas. Im stated, "In the ADC field, global pharmaceutical companies are actively adopting digital pathology AI-based Companion Diagnostics (CDx), where Lunit's analysis technology can significantly contribute." Lunit is currently developing biomarkers for ADC drugs using IHC analysis of immunostained slides and is also building a TKI response-prediction model using morphological pattern analysis. Im also added, "If AI quantifies drug-specific response patterns, it will allow us to connect both companion diagnostics and patient-specific treatment in the future." At this ESMO Congress 2025, Lunit also presented research on renal cell carcinoma and non-small cell lung cancer in addition to colorectal cancer. In the renal cell carcinoma study, the immune-activated patient group showed a significantly higher ORR of 60.5% in the nivolumab + ipilimumab combination therapy compared to the non-activated group (23.2%). In the NSCLC study, the immune-activated phenotype showed a superior response in a Japanese multi-center patient cohort, confirming the reproducibility of the AI model. Im said, "AI pathology analysis is not limited to a specific cancer type." She added, "We are conducting multi-cancer expansion studies to apply it to early treatment stages and adjuvant therapies." Ultimately, the assessment is that AI is no longer a future technology but becoming established as a practical tool that is changing treatment strategies in real-world clinical settings. Im concluded, "AI pathology analysis is not limited to a specific cancer type. Lunit is conducting multi-cancer expansion studies so that it can be applied to early treatment stages and adjuvant therapies."
- Company
- Boehringer withdraws 1 lawsuit over unlisted Trajenta patent
- by Kim, Jin-Gu Oct 22, 2025 06:11am
- Product photo of Trajenta Boehringer Ingelheim has voluntarily withdrawn one of its ongoing patent disputes involving unlisted Trajenta (linagliptin) patents. Attention is focused on whether this withdrawal will lead to the conclusion of other ongoing disputes, as Boehringer Ingelheim has been pursuing unlisted patent challenges even after the launch of Trajenta generics. According to the pharmaceutical industry, on October 21 Boehringer Ingelheim voluntarily withdrew a lawsuit seeking to cancel a patent invalidation ruling against 16 companies, including Genuone Sciences, on October 20. The patent was registered under the name "Treatment of Diabetes in Patients with Insufficient Glycemic Control Despite Therapy with Oral or Non-oral Agents for Diabetes." It involves the combination of linagliptin and sulfonylurea (SU). This patent was one of the unlisted Trajenta-related patents. Boehringer Ingelheim filed this patent in January 2020, and it was registered with the Korean Intellectual Property Office in April 2022. However, it was not listed in the Ministry of Food and Drug Safety (MFDS) patent registry. Generic companies, anticipating the launch of Trajenta generics in June 2023, challenged this unlisted patent to alleviate patent risk. Companies that filed the invalidation trial included Genuone Sciences, Kukje Pharm, Kyungbo Pharmaceutical, KyungDong Pharm, DongKoo Bio & Pharma, Dongwha Pharm, Daewon Pharm, Boryung, Shinil Pharm, Aju Holdings, Alvogen Korea, Ildong Pharmaceutical, Jeil Pharmaceutical, Korea Prime Pharm, Korea Huons, and Hanlim Pharm. The substance patent for Trajenta expired while the dispute was ongoing. Twenty-nine companies launched their generics when substance patent expired in May of last year. However, Trajenta's unlisted patents continue to pose a risk to generic companies. If generic companies lose unlisted patent disputes, their generic sales could be deemed patent infringement. In such a scenario, Boehringer Ingelheim could file for preliminary injunctions to halt sales and pursue damages through lawsuits. In May of this year, the Intellectual Property Trial and Appeal Board ruled in favor of the generic companies. Boehringer Ingelheim subsequently appealed to the Patent Court. However, it voluntarily withdrew the lawsuit approximately five months later. This concluded one of the multiple lawsuits surrounding Trajenta's unlisted patents. The pharmaceutical industry's attention is now focused on whether the remaining disputes over Trajenta's unlisted patents will also be resolved. Boehringer Ingelheim has registered over 10 unlisted Trajenta patents, in addition to the linagliptin-sulfonylurea combination patent. Generic companies have filed circumvention and invalidation trials against each of these patents, and the disputes are ongoing. If Boehringer Ingelheim voluntarily withdraws the remaining unlisted patent lawsuits, the patent risks surrounding Trajenta generics are mostly expected to be resolved.
- Company
- Targeting EZH1·2…Hanmi unveils next-gen anticancer agent
- by Hwang, byoung woo Oct 22, 2025 06:10am
- Hanmi Pharmaceutical has unveiled another pillar of its new anticancer pipeline at the ESMO Congress 2025 (European Society for Medical Oncology). The company presented Phase 1 clinical trial results of 'EZH1/2 dual inhibitor (HM97662),' suggesting possibilities for a new anticancer mechanism that could overcome drug resistance. DailyPharm met with Young Su Noh, Director of Hanmi's Oncology Clinical Team, and heard about the clincal significance of HM97662 and the company's future development strategy. Young Su Noh, Director of Hanmi "Evidence confirmed for resistance inhibition and maintained response… proving the value of EZH1 co-inhibition" According to the poster presentation, HM97662 secured safety and tolerability and confirmed initial anti-tumor responses in a Phase 1 clinical trial involving patients with advanced or metastatic solid tumors. A total of 28 patients received treatment across seven dose cohorts (50 to 350mg QD). Partial response (PR) and long-term stable disease (SD) were observed in some patients. Director Noh said, "HM97662 was developed based on a mechanism that simultaneously inhibits both EZH1 and EZH2, showing superiority over single inhibition in terms of resistance suppression and response durability." He explained, "Since EZH1 is compensatorily activated, leading to resistance when EZH2 is inhibited alone, the approach of targeting both is favorable." Noh also stated, "Long-term SD was also confirmed in the clinical trial, which shows the possibility that EZH1 co-inhibition contributes to maintaining the response," and added, "Although we are still in the early stages, we plan to continue establishing clinical evidence." The presentation highlighted a PR observed in a patient with SMARCA4 deficiency. Noh said, "The observation of PR in a patient with a SMARCA4 mutation is highly significant," and explained, "This patient group is high-risk with typically low response rates to existing treatments, and the results suggest that the EZH1/2 dual inhibition strategy has the potential to show therapeutic activity even in patients with molecular mutations." He added, "In solid tumors, PRC2 (Polycomb Repressive Complex 2) complex abnormalities are often involved, while EZH2 mutations are directly implicated in blood cancers. HM97662 is a candidate that reflects these molecular characteristics and can expand treatment possibilities even in solid tumors." Hanmi Pharmaceutical is currently conducting the Phase 1 trial of HM97662 in Korea and Australia and is considering expanding to the U.S. Noh said, "Hanmi Pharmaceutical is focusing on small cell carcinoma, ovarian cancer, and prostate cancer as cancer types where EZH1/2 dual inhibition may be particularly effective. Although we started with a broad scope of metastatic solid tumors, we will gradually narrow down to cancer types with clearer responses." "Combining global collaboration and in-house development… building the Hanmi oncology portfolio" Although Hanmi Pharmaceutical's presentation at ESMO Congress 2025 focused on HM97662, the company is building a diverse portfolio of other anti-cancer pipelines. Young Su Noh, Director of HanmiNoh said, "Out-licensing (L/O) is an important process, but it is not the only goal." He added, "We are also considering a strategy of simultaneously pursuing in-house development and commercialization to target areas where patient access is limited in Korea and Asia." Noh stated, "Global pharmaceutical companies are showing interest, and we are preparing for combination clinical trials," and added, "We have confirmed the possibility of synergy in preclinical studies when combining with immunotherapies, targeted therapies, or chemotherapy, and we plan to expand this into clinical trials." Hanmi plans to strengthen the clinical evidence for the EZH1/2 mechanism based on these results while also entering combination clinical trials with immunotherapies. Noh said, "We plan to secure dose and tolerability with monotherapy first, and then expand to combination strategies." He explained, "We are securing preclinical data that suggests the possibility of synergy when used in combination with chemotherapy and immunotherapy." Noh particularly mentioned Hanmi Pharmaceutical's ongoing oncology research efforts, noting that the company is pursuing a long-term, sustainable commercialization strategy. "Hanmi Pharmaceutical is known for obesity and metabolic diseases, but we also have long-standing research experience and accumulated capabilities in the oncology field," he said. "Our past clinical and research experience is driving our current anti-cancer pipeline." Noh also expressed confidence, stating, "Hanmi has already had multiple global technology transfer experiences, and we are developing returned projects in-house. We are building the foundation to complete new drugs with proprietary capacity, such as the EZH1/2 dual inhibitor." Following this trend, Hanmi is also accelerating its expansion into next-generation research areas. Noh commented, "In addition to immunotherapy combinations, we are also conducting research on next-generation platforms like mRNA and TPD (Targeted Protein Degradation)," and added, "Even after ESMO, we will continue to make subsequent presentations at major conferences like SITC to bring our oncology portfolio into public view.
- Company
- ‘Age-specific vaccination needed to address unmet needs'
- by Son, Hyung Min Oct 22, 2025 06:09am
- Professor Jung-Hyun Choi, Division of Infectious Diseases, Eunpyeong St. Mary A new vaccine targeting the largest number of serotypes in the pneumococcal market has been introduced in Korea. MSD Korea plans to address unmet needs in pneumococcal disease through age-specific prevention strategies, following the release of its adult vaccine, which follows pediatric vaccines. On the 21st, MSD Korea held a press conference at the JW Marriott Hotel Seoul to mark the domestic approval of the pneumococcal vaccine Capvaxive and introduced the vaccine's clinical evidence and preventive efficacy. Capvaxive, which was approved in Korea in August, is indicated for adults aged 18 and older to prevent invasive disease and pneumonia caused by 21 pneumococcal serotypes (3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, 35B). Notably, it covers 8 unique serotypes (15A, 15C, 16F, 23A, 23B, 24F, 31, 35B) not included in Pfizer’s Prevnar 20, which recently entered the Korean market. These serotypes are clinically significant for preventing pneumococcal disease in adults, as they are detected in over 30% of infected adults aged 65 and older. Pneumococcal disease is an infection caused by Streptococcus pneumoniae, which has approximately 100 different serotypes. In the United States, over 150,000 adults are hospitalized annually for pneumococcal pneumonia. As a result, pharmaceutical companies have continued competition to develop vaccines that cover more serotypes, and the emergence of the 21-valent vaccine Capvaxive represents an evolution in this serotype coverage competition. Capvaxive demonstrated non-inferiority compared to the existing 20-valent protein-conjugated vaccine (PCV20) in the Phase III STRIDE-3 trial. In this study involving 2,662 adults with no prior pneumococcal vaccination history, Capvaxive showed non-inferior immune responses to the 20-valent vaccine for shared serotypes and even higher antibody responses for unique serotypes. Furthermore, enhanced immune responses were observed in certain serotypes when administered as a booster to individuals previously vaccinated with 13-valent, 15-valent protein-conjugated vaccines, or the 23-valent polysaccharide vaccine. Professor Jung-Hyun Choi of the Division of Infectious Diseases at Eunpyeong St. Mary's Hospital emphasized, “Herd immunity formed solely through the National Immunization Program (NIP) for children is insufficient to prevent adult infections completely. The need for adult-specific vaccines is growing as serotypes with high antibiotic resistance and those not included in existing vaccines are increasing.” He further noted, “The 21-valent vaccine has a completely different coverage spectrum compared to existing vaccines. This is expected to provide approximately 20-30% higher preventive efficacy in adults.” Serotype replacement phenomenon causes prevention gaps…Need for separate pediatric/adult strategies highlighted Jaeyong Cho, Executive Director of MSD Korea’s Vaccine Business Unit MSD Korea has clearly differentiated its vaccine strategy by age group. It has obtained approval for the pediatric ‘Vaxneuvance (15-valent)’ and the adult ‘Capvaxive (21-valent)’ separately to establish a tailored prevention system considering age-specific immune characteristics and infection risks. This strategy pursues an age-optimized approach, differing from Pfizer's Prevnar series, which uses the same vaccine across all age groups. MSD Korea emphasizes that Capvaxive is specifically tailored for adults. While the overall pneumococcal infection rate has decreased due to the availability of various vaccines, a prevention gap still exists due to serotype replacement. Analysis indicates that infections caused by serotypes not included in vaccines developed since 2014 are increasing, necessitating a new response focused on the adult population. Reflecting this global trend, the U.S. Centers for Disease Control and Prevention (CDC) recently updated its pneumococcal vaccination guidelines, recommending vaccination for adults aged 50 and older, expanding the age range from the previously recommended 65 and older. The CDC specifically emphasized the need for broader serotype coverage, stating that even individuals who previously received the 13-valent vaccine should consider additional vaccination with the 20-, 21-, or 23-valent vaccines. Professor Choi stated, "Compared to PCV20, the preventive efficacy of Capvaxive against invasive pneumococcal disease caused by unique serotypes is expected to be 21-30%. The preventive effect against PCV20-specific serotypes when using Capvaxive appears to decrease by about 8%.“ He further emphasized, ”While the preventive effect is similar for some common serotypes, additional protection can be secured through Capvaxive’s unique serotypes. Ultimately, an age-specific customized vaccine strategy is the most realistic and efficient approach." Jaeyong Cho, Executive Director of MSD Korea’s Vaccine Business Unit, said, “By providing age-specific vaccines, we will reduce the risk of hospitalization and death from adult pneumococcal disease, alleviate healthcare costs, and ease the socioeconomic burden of an aging society. Capvaxive will become the new standard for adult pneumococcal prevention.” He added, “We plan to launch Capvaxive in the first or second quarter of next year and pursue collaboration with domestic pharmaceutical companies for its rollout at an appropriate time.”
- Company
- FutureChem to apply for cond approval of Ludotadipep in KOR
- by Hwang, byoung woo Oct 22, 2025 06:08am
- Results for FutureChem's next-generation radioligand therapy (RLT) ‘Ludotadipep (FC705)’, presented at the European Society for Medical Oncology (ESMO 2025), are drawing significant attention. In a multiple-dose clinical trial for patients with metastatic castration-resistant prostate cancer (mCRPC), the cumulative radiation dose to major organs was found to be below international safety standards, and tolerability was maintained even with repeated administration. DailyPharm met with Chansoo Park, Executive Director of Development at FutureChem, in Berlin to discuss the significance of these results and the company's future development strategy. ESMO2025 Poster Presentation by Chan-soo Park, Executive Director of Development, FutureChem " “Albumin-binding structure extends …alleviates safety concerns" Director Park stated, “This data proves that the albumin-binding structure extends the substance’s half-life in the body while enhancing tumor accumulation without increasing exposure to normal organs.” The study, a Phase II clinical trial that was conducted in Korea, analyzed a total of 68 treatment cycles in 20 mCRPC patients. At the first dose, the highest absorbed doses were observed in the salivary glands (1.22±0.53 Gy/GBq) and kidneys (0.674±0.33 Gy/GBq), while the lowest dose was in the bone marrow (0.053±0.011 Gy/GBq). After repeated administration, the salivary gland dose decreased significantly (p
- Company
- 'Will accelerate innovation through AI and clinical focus'
- by Hwang, byoung woo Oct 21, 2025 06:20am
- “AI is now at the heart of drug development. We must make our clinical support system more flexible and manage budgets more efficiently.” At the 2025 European Society for Medical Oncology (ESMO)—one of the world’s largest cancer conferences—Dr. Yeong-Min Park, Director of the Korea Drug Development Foundation (KDDF), stressed the importance of practical support measures to keep pace with global drug development trends. “Trends rapidly shifting around AI and oncology... an unavoidable trend for Korea as well” Director Park cited ‘AI (Artificial Intelligence)’ as the most notable keyword at this year's ESMO 2025. “Understanding global R&D trends is essential to identifying competitive fields. As KDDF prepares its next 5-year plan, this conference has provided valuable insights for discussion.” Indeed, many global pharmaceutical companies showcased AI-based drug candidate discovery, virtual clinical data utilization, and combination therapy optimization at this year’s meeting. Notably, ESMO also released official guidance titled “ESMO Guidance on the Use of Large Language Models in Clinical Practice (ELCAP)”, outlining the use of large language models (LLMs) in clinical practice. Director Park remarked, "The number of AI-related sessions was remarkably high, and the presentation quality was exceptionally strong. The government is also shifting its focus to AI starting next year, and the use of AI in the field of oncology will become an unavoidable trend. We also need to connect AI with our clinical and data businesses to accelerate innovation." At the ESMO2025 conference Hall in Berlin, booths from Korean companies like Lunit and Prestige Biopharma were set up throughout the conference halls. Additionally, the Korea National Enterprise for Clinical Trials (KoNECT) set up a booth to support domestic companies in securing investors and global partnerships. The Korea Drug Development Fund (KDDF) also participated in this support effort. Director Park said, “We have seen domestic companies actively engaging on-site. At this ESMO, which has grown to rival ASCO in scale, the presence of Korean companies was distinctly felt.” “KDDF plans to focus on clinical strengthening measures in its next five-year plan” For KDDF, participation in ESMO 2025 served not merely as observation but as a key step in policy planning. Director Park noted that the organization is currently meeting with industry leaders on-site to refine its future support framework. KDDF’s upcoming five-year plan is expected to include “enhanced clinical support” and “establishing an AI-driven drug development foundation” as its core initiatives. Director Park stressed execution and flexibility as critical elements for success, identifying three key factors in drug development: clinical support systems, budget management, and responsiveness to emerging trends. To this end, he stated that discussions are underway to allow clinical support funding to be flexibly adjusted within the scope of the preliminary feasibility study (PFS), rather than being constrained by a fixed budget. To enable this, KDDF is considering expanding the authority of evaluation committees and adjusting weightings based on clinical stage. Director Park mentioned, "Even if the total budget remains unchanged, we can adjust its allocation per project. We should allocate more to projects that require more funding and reduce allocations to those that require less. This approach will lead to tangible results.“ Finally, he added, ”Ultimately, new drug development hinges on the flexibility of the clinical support system and budget management. KDDF must chart a course that keeps pace with current trends while ensuring our companies gain competitiveness on the global stage."
- Company
- Pluvicto demonstrates first-line efficacy in prostate cancer
- by Hwang, byoung woo Oct 21, 2025 06:19am
- Novartis’ radioligand therapy Pluvicto (lutetium vipivotide tetraxetan; [¹⁷⁷Lu]Lu-PSMA-617) has demonstrated a clinically meaningful benefit as first-line treatment in patients with metastatic hormone-sensitive prostate cancer (mHSPC). This is considered the first Phase III evidence confirming Pluvicto's potential to extend beyond existing castration-resistant prostate cancer (mCRPC) into the first-line (mHSPC) setting. Results of the Phase III PSMAddition trial are being presented at ESMO 2025 The findings from the Phase III PSMAddition trial, presented on October 19 at the ESMO 2025 Congress by Professor Scott T. Tagawa of Weill Cornell Medicine (U.S.), confirm the potential for Pluvicto to move earlier in the prostate cancer treatment paradigm. This study enrolled 1,144 patients with PSMA-positive mHSPC who were either treatment-naive (≤45 days) or had received minimal prior therapy. Patients were randomized 1:1 to either the combination group (572 patients) receiving Pluvicto + androgen deprivation therapy (ADT) + ARPI, or the ADT + ARPI monotherapy group (572 patients). Pluvicto was administered at 7.4 GBq every 6 weeks for up to six cycles, with stratification by disease volume (high vs low), age (≥ 70 years), and prior local treatment history of the primary tumor. The primary endpoint was radiographic progression-free survival (rPFS), with secondary endpoints including overall survival (OS), objective response rate (ORR), safety, and quality of life (QoL). At a median follow-up of 23.6 months, neither group had reached median rPFS, but the Pluvicto combination group showed a 28% lower risk of disease progression or death. Overall survival (OS) also had not reached its median, but showed an improvement trend in the Pluvicto group. The objective response rate (ORR) was 85.3% vs 80.8%, and rPFS improvement was consistent across all predefined subgroups. Safety profile consistent with existing data… No impact on quality of life Treatment-emergent adverse events (TEAEs) were reported in 98.4% vs 96.6% of patients, with grade ≥ 3 events occurring in 50.7% vs 43.0%, respectively. The most common AEs were dry mouth (46.5%), fatigue, and nausea, which were mostly mild (Grade 1–2). Hematologic toxicities (anemia, neutropenia, thrombocytopenia) were more frequent in the combination group but were generally manageable. There were no significant differences between groups in quality of life measures (Fact-P, BPI-SF, etc.). Scott T. Tagawa, Weill Cornell Medicine, USA Professor Tagawa stated, “Combination therapy with Pluvicto plus ADT and ARPI significantly improved radiographic progression-free survival (rPFS) in PSMA-positive mHSPC patients. The effect was consistent across subgroups, safety was consistent with the existing profile, and no deterioration in patient quality of life was observed.” He further emphasized, “These results provide evidence that an early combination strategy with Pluvicto may offer clinical benefit.” Professor Ana C. Garrido-Castro (Dana-Farber Cancer Institute/Harvard Medical School), who served as a discussant in the same session, noted, “PSMAddition is the first large-scale Phase III trial demonstrating that PSMA-targeted radiotherapeutics achieve meaningful efficacy even in the hormone-sensitive stage.” PSMAddition demonstrated that Pluvicto has emerged as a candidate for a new standard of care as a combination therapy in the early stages of prostate cancer using radioligand therapy (RLT). These findings are expected to serve as key evidence supporting future label expansion into the hormone-sensitive setting.
- Company
- Eliquis 13%, Xarelto 49% of DOAC Generics mkt
- by Kim, Jin-Gu Oct 21, 2025 06:19am
- In Korea’s direct oral anticoagulant (DOAC) market, Eliquis (apixaban) generics have regained a 13% market share within a year of re-entering the market. However, that figure remains roughly half the level prior to their withdrawal. By contrast, Xarelto (rivaroxaban) generics have continued to expand their presence, reaching a 49% market share, has raised its market share to around 49%, poised to overtake the original. Analysis suggests that when Eliquis generics withdrew from the market, the focus shifted to Xarelto generics, making market penetration difficult for the Eliquis generics. 1 year after the re-entry of Eliquis generics... Market share around 13% According to the market research institution UBIST on the 20th, Eliquis generics recorded combined prescription sales of KRW 1.9 billion in Q3. Its market share in the apixaban-based DOAC treatment market stands at around 13%. Eliquis generics re-entered the DOAC market in Q4 last year. Eliquis generics initially entered the market in June 2019, when several companies launched products following first- and second-instance patent rulings in their favor. However, the situation reversed in April 2021 when the Supreme Court overturned the lower court rulings and sided with the originator, BMS. As a result, generic manufacturers immediately withdrew their products. This led to a three-and-a-half-year gap before their re-entry in September 2023, just ahead of the patent expiration on the apixaban compound. Quarterly prescriptions of Eliquis and Eliquis generics Since re-entering, Eliquis generics have struggled to regain momentum. Before withdrawal (in Q1 2021), total prescriptions had reached KRW 3.7 billion, representing a 24% share of the apixaban DOAC market. Compared to just before withdrawal, prescription sales are at half the level, and market share shows a difference exceeding 10% points. Although prescription sales have gradually increased since its market re-entry, evaluations indicate this growth falls short of expectations. Share of Xarelto generics' surged after Eliquis generics withdrawn from the market Analysis suggests that the market momentum shifted decisively toward Xarelto generics during Eliquis generics’ three-year absence, The first Xarelto generics were launched in Q2 2021, coinciding with the Supreme Court’s reversal in the Eliquis case. Although Xarelto’s substance patent did not expire until October 2021, five companies entered the market early. After patent expiry in Q4 2021, Xarelto generics rapidly expanded both prescription volume and market share. By Q1 2023, total prescriptions had reached KRW 3.7 billion, capturing over 30% of the rivaroxaban DOAC market. In Q3 this year, prescription sales further increased to KRW 7.2 billion. Its market share in the rivaroxaban market rose to around 49%. The pharmaceutical industry anticipates that it will soon surpass the original drug's market share. Quarterly prescriptions of major DOAC drugs in Korea Consequently, the positions of Eliquis generics and Xarelto generics have reversed. After Eliquis generics withdrew from the market due to the Supreme Court's reversal ruling, generic companies shifted their marketing focus to Xarelto generics, leading to increased prescription volume and market share, according to analysis. Reversed fortunes…Eliquis generic sales halted·focus on Xarelto generic sales intensifies In fact, some companies have not launched generics even after Eliquis' substance patent expired. Yuhan Corporation sold its Eliquis generic ‘Yuhan Apixaban’ before the Supreme Court ruling, achieving cumulative prescriptions worth over KRW 2.5 billion. However, it has stopped selling the product since the patent gap emerged. Instead, Yuhan has focused on selling its Xarelto generic ‘Yuhan Rivaroxaban’, achieving cumulative prescriptions worth KRW 3.3 billion. Hanmi Pharmaceutical made a similar shift, halting sales of its Eliquis generic ‘Apixban’ and focusing on its Xarelto generic, Riroxaban, which recorded KRW 2.2 billion in Q3 — the highest among all Xarelto generics. Chong Kun Dang and Samjin Pharmaceutical continue to market both Eliquis and Xarelto generics, though the latter’s performance is nearly twice as strong. Chong Kun Dang’s Eliquis generic Liquisia recorded KRW 600 million in Q3 prescriptions, compared to the KRW 1.2 billion made with its Xarelto generic Riroxia. Similarly, Samjin’s Eliquis generic Elxaban posted KRW 700 million, while its Xarelto generic Rivoxaban reached KRW 1.2 billion.
